A new, alternative risk score for sarcopenia in Chinese patients with type 2 diabetes mellitus
Abstract Objective To develop a new, alternative sarcopenia risk score to screen for sarcopenia in type 2 diabetes patients in China and to demonstrate its validity. Research design and methods The data for this study came from a multicenter, cross-sectional study that had been designed to estimate...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-05-01
|
| Series: | European Journal of Medical Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40001-023-01127-1 |
| _version_ | 1797827674517798912 |
|---|---|
| author | Qinghua He Xiuzhi Wang Caizhe Yang Xiaoming Zhuang Yanfen Yue Hongjiang Jing Jing Hu Mingxiao Sun Lixin Guo |
| author_facet | Qinghua He Xiuzhi Wang Caizhe Yang Xiaoming Zhuang Yanfen Yue Hongjiang Jing Jing Hu Mingxiao Sun Lixin Guo |
| author_sort | Qinghua He |
| collection | DOAJ |
| description | Abstract Objective To develop a new, alternative sarcopenia risk score to screen for sarcopenia in type 2 diabetes patients in China and to demonstrate its validity. Research design and methods The data for this study came from a multicenter, cross-sectional study that had been designed to estimate the prevalence of sarcopenia among adults with type 2 diabetes and had been conducted in several hospitals in Beijing, China. A total of 1125 participants were randomly divided into two groups: an exploratory population and a validation population. A multivariable logistic regression model using the backward stepwise likelihood ratio method to estimate the probability of sarcopenia was fitted with candidate variables in the exploratory population. A new, alternative sarcopenia risk score was developed based on the multivariable model. The internal and external validations were performed in the exploratory and validation populations. The study was registered at Chinese Clinical Trial Registry (ChiCTR-EOC-15006901). Results The new, alternative sarcopenia risk score included five variables: age, gender, BMI, total energy intake per day, and the proportion of calories supplied by protein. The score ranged from − 2 to 19. The area under the receiver operating characteristic (ROC) curve of the risk score for the prediction of sarcopenia in type 2 diabetes patients was 0.806 (95% CI 0.741–0.872) and 0.836 (95% CI 0.781–0.892) in the exploratory and validation populations, respectively. At the optimal cutoff value of 12, the sensitivity and specificity of the score for the prediction of sarcopenia were 70.9% and 81.0% in the exploratory population and 53.7% and 88.8% in the validation population, respectively. The Hosmer–Lemeshow goodness-of-fit test showed a good calibration with the risk score in external validation (χ 2 = 4.459, P = 0.813). Conclusions The new, alternative sarcopenia risk score appears to be an effective screening tool for identification of sarcopenia in Chinese patients with type 2 diabetes in clinical practice. Clinical trial registration Chinese Clinical Trial Registry, ChiCTR-EOC-15006901. |
| first_indexed | 2024-04-09T12:52:08Z |
| format | Article |
| id | doaj.art-e0c715a14f9a48f7b07005c4d53ae341 |
| institution | Directory Open Access Journal |
| issn | 2047-783X |
| language | English |
| last_indexed | 2024-04-09T12:52:08Z |
| publishDate | 2023-05-01 |
| publisher | BMC |
| record_format | Article |
| series | European Journal of Medical Research |
| spelling | doaj.art-e0c715a14f9a48f7b07005c4d53ae3412023-05-14T11:12:09ZengBMCEuropean Journal of Medical Research2047-783X2023-05-0128111010.1186/s40001-023-01127-1A new, alternative risk score for sarcopenia in Chinese patients with type 2 diabetes mellitusQinghua He0Xiuzhi Wang1Caizhe Yang2Xiaoming Zhuang3Yanfen Yue4Hongjiang Jing5Jing Hu6Mingxiao Sun7Lixin Guo8Department of Endocrinology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical SciencesDepartment of Endocrinology, Pinggu Hospital, Beijing Traditional Chinese Medicine HospitalDepartment of Endocrinology, Air Force Characteristic Medical CenterDepartment of Endocrinology, Fuxing Hospital Affiliated to Capital Medical UniversityDepartment of Nutrition, Pinggu Hospital, Beijing Traditional Chinese Medicine HospitalDepartment of Nutrition, Air Force Characteristic Medical CenterDepartment of Nutrition, Fuxing Hospital Affiliated to Capital Medical UniversityDepartment of Endocrinology, Beijing Yide HospitalDepartment of Endocrinology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical SciencesAbstract Objective To develop a new, alternative sarcopenia risk score to screen for sarcopenia in type 2 diabetes patients in China and to demonstrate its validity. Research design and methods The data for this study came from a multicenter, cross-sectional study that had been designed to estimate the prevalence of sarcopenia among adults with type 2 diabetes and had been conducted in several hospitals in Beijing, China. A total of 1125 participants were randomly divided into two groups: an exploratory population and a validation population. A multivariable logistic regression model using the backward stepwise likelihood ratio method to estimate the probability of sarcopenia was fitted with candidate variables in the exploratory population. A new, alternative sarcopenia risk score was developed based on the multivariable model. The internal and external validations were performed in the exploratory and validation populations. The study was registered at Chinese Clinical Trial Registry (ChiCTR-EOC-15006901). Results The new, alternative sarcopenia risk score included five variables: age, gender, BMI, total energy intake per day, and the proportion of calories supplied by protein. The score ranged from − 2 to 19. The area under the receiver operating characteristic (ROC) curve of the risk score for the prediction of sarcopenia in type 2 diabetes patients was 0.806 (95% CI 0.741–0.872) and 0.836 (95% CI 0.781–0.892) in the exploratory and validation populations, respectively. At the optimal cutoff value of 12, the sensitivity and specificity of the score for the prediction of sarcopenia were 70.9% and 81.0% in the exploratory population and 53.7% and 88.8% in the validation population, respectively. The Hosmer–Lemeshow goodness-of-fit test showed a good calibration with the risk score in external validation (χ 2 = 4.459, P = 0.813). Conclusions The new, alternative sarcopenia risk score appears to be an effective screening tool for identification of sarcopenia in Chinese patients with type 2 diabetes in clinical practice. Clinical trial registration Chinese Clinical Trial Registry, ChiCTR-EOC-15006901.https://doi.org/10.1186/s40001-023-01127-1SarcopeniaType 2 diabetesRisk score |
| spellingShingle | Qinghua He Xiuzhi Wang Caizhe Yang Xiaoming Zhuang Yanfen Yue Hongjiang Jing Jing Hu Mingxiao Sun Lixin Guo A new, alternative risk score for sarcopenia in Chinese patients with type 2 diabetes mellitus European Journal of Medical Research Sarcopenia Type 2 diabetes Risk score |
| title | A new, alternative risk score for sarcopenia in Chinese patients with type 2 diabetes mellitus |
| title_full | A new, alternative risk score for sarcopenia in Chinese patients with type 2 diabetes mellitus |
| title_fullStr | A new, alternative risk score for sarcopenia in Chinese patients with type 2 diabetes mellitus |
| title_full_unstemmed | A new, alternative risk score for sarcopenia in Chinese patients with type 2 diabetes mellitus |
| title_short | A new, alternative risk score for sarcopenia in Chinese patients with type 2 diabetes mellitus |
| title_sort | new alternative risk score for sarcopenia in chinese patients with type 2 diabetes mellitus |
| topic | Sarcopenia Type 2 diabetes Risk score |
| url | https://doi.org/10.1186/s40001-023-01127-1 |
| work_keys_str_mv | AT qinghuahe anewalternativeriskscoreforsarcopeniainchinesepatientswithtype2diabetesmellitus AT xiuzhiwang anewalternativeriskscoreforsarcopeniainchinesepatientswithtype2diabetesmellitus AT caizheyang anewalternativeriskscoreforsarcopeniainchinesepatientswithtype2diabetesmellitus AT xiaomingzhuang anewalternativeriskscoreforsarcopeniainchinesepatientswithtype2diabetesmellitus AT yanfenyue anewalternativeriskscoreforsarcopeniainchinesepatientswithtype2diabetesmellitus AT hongjiangjing anewalternativeriskscoreforsarcopeniainchinesepatientswithtype2diabetesmellitus AT jinghu anewalternativeriskscoreforsarcopeniainchinesepatientswithtype2diabetesmellitus AT mingxiaosun anewalternativeriskscoreforsarcopeniainchinesepatientswithtype2diabetesmellitus AT lixinguo anewalternativeriskscoreforsarcopeniainchinesepatientswithtype2diabetesmellitus AT qinghuahe newalternativeriskscoreforsarcopeniainchinesepatientswithtype2diabetesmellitus AT xiuzhiwang newalternativeriskscoreforsarcopeniainchinesepatientswithtype2diabetesmellitus AT caizheyang newalternativeriskscoreforsarcopeniainchinesepatientswithtype2diabetesmellitus AT xiaomingzhuang newalternativeriskscoreforsarcopeniainchinesepatientswithtype2diabetesmellitus AT yanfenyue newalternativeriskscoreforsarcopeniainchinesepatientswithtype2diabetesmellitus AT hongjiangjing newalternativeriskscoreforsarcopeniainchinesepatientswithtype2diabetesmellitus AT jinghu newalternativeriskscoreforsarcopeniainchinesepatientswithtype2diabetesmellitus AT mingxiaosun newalternativeriskscoreforsarcopeniainchinesepatientswithtype2diabetesmellitus AT lixinguo newalternativeriskscoreforsarcopeniainchinesepatientswithtype2diabetesmellitus |